Providence Health & Services

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.providence.org

Clinical Trials

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: TAS 102
Drug: Oxaliplatin

First Posted Date: 2020-06-05

Last Posted Date: 2024-03-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 13

Registration Number: NCT04417699

Locations: 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
Columbia University Irving Medical Center/NYPH, New York, New York, United States

and more 1 locations

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Breast Neoplasms

Interventions: Drug: Pembrolizumab
Drug: IRX 2

First Posted Date: 2020-05-04

Last Posted Date: 2024-06-21

Lead Sponsor: Providence Health & Services

Target Recruit Count: 12

Registration Number: NCT04373031

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Phase 4

Suspended

Conditions: 2019 Novel Coronavirus
SARS-CoV-2
COVID-19
Corona Virus Infection
2019-nCoV

Interventions: Dietary Supplement: Vitamin C
Drug: Hydroxychloroquine

First Posted Date: 2020-04-06

Last Posted Date: 2020-09-16

Lead Sponsor: Providence Health & Services

Target Recruit Count: 13

Registration Number: NCT04334967

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Phase 3

Completed

Conditions: Multiple Sclerosis
Infusion Reaction

Interventions: Drug: cetrizine
Drug: diphenhydramine

First Posted Date: 2019-11-25

Last Posted Date: 2024-03-04

Lead Sponsor: Providence Health & Services

Target Recruit Count: 19

Registration Number: NCT04175834

Locations: 🇺🇸
Providence Neurological Specialties West, Portland, Oregon, United States

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: BRAF V600E Mutation Present
Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8
Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
Metastatic Thyroid Gland Carcinoma
Refractory Thyroid Gland Carcinoma
Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
BRAF NP_004324.2:p.V600M

Interventions: Drug: Binimetinib
Drug: Encorafenib
Biological: Nivolumab

First Posted Date: 2019-08-20

Last Posted Date: 2024-11-18

Lead Sponsor: Providence Health & Services

Target Recruit Count: 24

Registration Number: NCT04061980

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Achieving the Quadruple Aim by Reducing Burnout

Not Applicable

Completed

Conditions: Burnout, Professional

Interventions: Behavioral: Compassion Curriculum

First Posted Date: 2018-11-19

Last Posted Date: 2018-11-19

Lead Sponsor: Providence Health & Services

Target Recruit Count: 341

Registration Number: NCT03746574

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Phase 1

Terminated

Conditions: Glioblastoma
Cancer of Brain
Glioblastoma Multiforme
Brain Tumor

Interventions: Device: Tumor Treating Fields
Drug: Temozolomide
Radiation: Radiation Therapy

First Posted Date: 2018-10-15

Last Posted Date: 2024-03-04

Lead Sponsor: Providence Health & Services

Target Recruit Count: 7

Registration Number: NCT03705351

Locations: 🇺🇸
Providence St. Vincent Medical Center, Portland, Oregon, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Breast Neoplasm Female
Breast Cancer
Breast Carcinoma
Breast Tumor

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Bicalutamide

First Posted Date: 2018-08-29

Last Posted Date: 2024-10-26

Lead Sponsor: Providence Health & Services

Target Recruit Count: 30

Registration Number: NCT03650894

Locations: 🇺🇸
Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Melatonin in Patients With Multiple Sclerosis (MS).

Early Phase 1

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: 3 mg Melatonin
Drug: 5 mg Melatonin

First Posted Date: 2018-04-13

Last Posted Date: 2023-08-04

Lead Sponsor: Providence Health & Services

Target Recruit Count: 30

Registration Number: NCT03498131

Locations: 🇺🇸
Providence MS Center, Portland, Oregon, United States

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Melanoma
Cell Cancer, Squamous
Carcinoma, Squamous Cell

Interventions: Drug: MEDI0562

First Posted Date: 2017-11-08

Last Posted Date: 2024-08-23

Lead Sponsor: Providence Health & Services

Target Recruit Count: 35

Registration Number: NCT03336606

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy